Literature DB >> 24684738

Non-adherence and measures to improve adherence in the topical treatment of psoriasis.

I Zschocke1, U Mrowietz, E Karakasili, K Reich.   

Abstract

Psoriasis is a chronic, recurrent immune-mediated skin disease with a 2-3% prevalence in the Western population, which severely affects patients' quality of life and poses a considerable socioeconomic challenge. The majority of individuals have psoriasis in limited areas and topical products are the mainstay of therapy according to existing guidelines. It is known that medication adherence rates are lower for topical treatment than for systemic treatment. Poor medication adherence is a major multidimensional problem for patients with chronic disorders as it is associated with unfavourable treatment outcomes, increased risk for development of concomitant diseases and inefficient use of health resources. Despite four decades of adherence research and the large number of studies that have identified the importance of medication non-adherence, there are relatively few studies reporting and designing effective strategies to improve adherence. The aim of this article was to report and describe non-adherence in the topical treatment of psoriasis, the factors that might contribute to this phenomenon, and which interventions have so far been developed for the management of chronic conditions. This article proposes that given that the barriers to medication adherence are complex and varied, solutions to improve adherence and thus clinical outcomes must be multifaceted and must also provide the possibility to be tailored according to each patient's individual needs. Such an individualized and comprehensive adherence-enhancing intervention would probably enable the successful long-term management of this disabling chronic condition.
© 2014 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24684738     DOI: 10.1111/jdv.12445

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  22 in total

1.  [Not Available].

Authors:  Firas George Hougeir; Fran E Cook-Bolden; David Rodriguez; Joshua M Berlin
Journal:  J Clin Aesthet Dermatol       Date:  2015-05

Review 2.  Adolescent Scalp Psoriasis: Update on Topical Combination Therapy.

Authors:  Emily Osier; Barbara Gomez; Lawrence F Eichenfield
Journal:  J Clin Aesthet Dermatol       Date:  2015-07

Review 3.  Calcipotriol/Betamethasone Dipropionate Foam: A Review in Plaque Psoriasis.

Authors:  Esther S Kim; James E Frampton
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

Review 4.  Evaluating Risk Tolerance from a Systematic Review of Preferences: The Case of Patients with Psoriasis.

Authors:  Juan Marcos Gonzalez
Journal:  Patient       Date:  2018-06       Impact factor: 3.883

5.  The Systemic Lupus Erythematosus Interventional Trials in Mainland China: A Continuous Challenge.

Authors:  Jingru Tian; Hang Zhou; Juan Liu; Feng Xiong; Ping Yi; Pengpeng Cao; Dorthy Fang; Bo Zhang; Qianjin Lu
Journal:  Front Immunol       Date:  2022-04-11       Impact factor: 8.786

6.  Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris.

Authors:  Catherine Queille-Roussel; Martin Olesen; John Villumsen; Jean-Philippe Lacour
Journal:  Clin Drug Investig       Date:  2015-04       Impact factor: 2.859

7.  Adherence to Oral and Topical Medications in Cutaneous Lupus Erythematosus is not Well Characterized.

Authors:  Michael E Farhangian; William W Huang; Steven R Feldman
Journal:  Dermatol Ther (Heidelb)       Date:  2015-04-22

8.  Poor adherence to oral and topical medication in 3096 dermatological patients as assessed by the Morisky Medication Adherence Scale-8.

Authors:  M Furue; D Onozuka; S Takeuchi; H Murota; M Sugaya; K Masuda; T Hiragun; S Kaneko; H Saeki; Y Shintani; Y Tsunemi; S Abe; M Kobayashi; Y Kitami; M Tanioka; S Imafuku; M Abe; N Inomata; D E Morisky; N Katoh
Journal:  Br J Dermatol       Date:  2014-12-09       Impact factor: 9.302

9.  Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12-17 years of age.

Authors:  M Gooderham; J-M Debarre; J Keddy-Grant; Z Xu; M Kurvits; M Goodfield
Journal:  Br J Dermatol       Date:  2014-10-22       Impact factor: 9.302

10.  Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real-life multicenter prospective observational cohort study.

Authors:  Anna Campanati; Laura Atzori; Concetta Potenza; Giovanni Damiani; Luca Bianchi; Monica Corazza; Rossana Tiberio; Francesca Prignano; Giuseppe Argenziano; Maria Concetta Fargnoli; Luca Stingeni; Annamaria Mazzotta; Ornella De Pità; Carlo Mazzatenta; Claudio Feliciani; Massimo Donini; Annamaria Offidani; Ketty Peris
Journal:  Dermatol Ther       Date:  2021-08-09       Impact factor: 3.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.